Over 10,000 children are currently battling cancer in Canada, with an additional 1,500 expected to be diagnosed this year. Tragically, nearly one in five will not survive. A common thread in these heartbreaking cases is that initial treatments often fail, and for many, there is no cure.
In response to this urgent challenge, we are delighted to announce that Sarcoma Research Canada is making a significant investment of $100,000 to the C17 Council through Childhood Cancer Canada and their 100% Fund.
The 100% Fund was established through a partnership between Childhood Cancer Canada, the C17 Council, and pediatric cancer advocates. This fund specifically targets pediatric and adolescent cancers that are resistant to current treatments—those that have not responded to available therapies. The 100% Fund supports research ranging from fundamental discovery to clinical trials, all with the goal of developing new, effective treatments that will improve survival rates and outcomes for these children.
We would like to express our heartfelt appreciation to the committee members and volunteers who offered their support in countless ways. We are deeply grateful for their unwavering commitment.
We are also pleased to recognize Mayor Steven Del Duca of Vaughan, whose leadership through the “Spirit of Generosity” campaign resulted in a remarkable donation of $5,000. We are truly appreciative of his commitment to Sarcoma Research Canada.
We are grateful to Jonathan Yen, lawyer at JCY Law, for his guidance and dedication.
Special thanks to the Venetian Banquet Hall and Mr. Joseph Mete, who go above and beyond to create a special and elegant event for Sarcoma Research Canada.
Above all, we extend our deepest gratitude to our participating schools, gracious sponsors, guests, and donors who played a crucial role in raising critical funds for Sarcoma Research Canada. Your participation and generosity have made all of this possible, and we celebrate each of you for championing such a worthy cause.
Together, we are making a meaningful difference in the fight against sarcoma cancer. Thank you for your continued support.
Carmela Ricco Caravaggio
CEO
